ILMN vs PACB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ILMN and PACB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ILMN and PACB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. Its high-throughput Revio system serves production genomics labs generating reference-quality genomes, while the newer benchtop Vega, a smaller and much cheaper instrument, aims to put HiFi long reads on more lab benches and introduce new users to the platform. Like most sequencing companies, PacBio runs a razor-and-blade model: it sells instruments, then earns recurring, higher-margin revenue from the consumables and reagents customers buy to run them. In Q1 2026 revenue was about $37.2 million, roughly flat year over year, as stronger consumables sales offset softer instrument and service revenue, and gross profit improved markedly from a gross loss a year earlier.

Full PACB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.
• PACB drivers: HiFi long-read differentiation; Vega benchtop and installed-base growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. For PACB, the dominant risk is that PacBio is unprofitable and burning cash: it posted a non-GAAP net loss near $36 million in Q1 2026 and depends on reaching breakeven before its cash cushion is stressed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ILMN if you believe its drivers more; PACB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ILMN and PACB guides.

ILMN. Illumina trades at a premium earnings multiple that reflects its platform dominance and consumables annuity, set against low-single-digit revenue growth and a slow-growing end market. Full-year 2025 revenue was about $4.34 billion, and the company guided fiscal 2026 to roughly $4.5 to $4.6 billion with operating margins recovering toward the low-to-mid 20s. All figures are approximate, tied to the June 2026 asOf date, and move with the share price and reported results; verify current numbers before relying on them.

PACB. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because PacBio is unprofitable, standard earnings multiples like P/E do not apply, and the stock is typically valued on revenue growth, gross-margin trajectory, and how quickly it can reach cash-flow breakeven relative to its cash balance. That makes instrument placements, consumables pull-through, and quarterly guidance far more important to the story than any single accounting figure, and it keeps the stock volatile.

Headline figures (approximate, June 2026): ILMN shows revenue (fy2025) ~$4.34 billion (approximate, verify), 2026 revenue guidance ~$4.5-4.6 billion, ~4-6% growth (company guidance, verify), consumables mix Majority of revenue is recurring consumables (razor-and-blades; verify), non-gaap operating margin (2026 guide) ~23.3-23.5% (company guidance, verify); PACB shows revenue (q1 2026) ~$37.2 million, roughly flat year over year, full-year 2026 revenue guidance ~$165 million to $175 million (company guidance), profitability Unprofitable; non-GAAP net loss ~$36 million (~$0.12 per share) in Q1 2026, narrower than a year earlier, gross margin Improving; gross profit turned positive (~$12.8 million) from a gross loss a year earlier.

ILMN and PACB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ILMN and PACB exposure against your real portfolio. It is not an investment adviser.